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Prevention of Surgical-Site Infections
To the Editor: I am concerned about the generalizability of the findings of Bode et al. (Jan. 7
issue)1 regarding the identification of nasal carriers of Staphylococcus aureus and the subsequent
use of mupirocin nasal ointment and chlorhexidine soap. First, it is unclear how the researchers
identified patients who were expected to be hospitalized for 4 or more days, since no specific
protocol is provided. Second, key surgical data
are lacking, despite the preponderance of surgical patients (88%). No data are provided on the
appropriateness of antimicrobial prophylaxis, in
particular the timing of administration; 84 of
828 surgical patients (10%) received no prophylaxis. Similarly, no data are provided to explain the
high rate of infection: among surgical patients,
S. aureus infection developed in 3.6% of those receiving prophylaxis and 8.4% of those receiving
placebo; 11 to 12% of patients had non–S. aureus
infection. Would the intervention be as effective
in a hospital with lower baseline rates of infection? Finally, it is unclear whether such a screen-
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ing protocol would work in settings with a high
rate of methicillin-resistant S. aureus infection, as
is the case in many community hospitals.2
Deverick J. Anderson, M.D., M.P.H.
Duke University Medical Center
Durham, NC
dja@duke.edu
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To the Editor: The study by Bode et al. highlights the value of mupirocin–chlorhexidine prophylaxis in preventing nosocomial S. aureus infection. Although resistance rates are low in the
Netherlands, where Bode et al. conducted their
study, our experience at the Providence Veterans
Affairs Medical Center has shown that increased
use of mupirocin can result in increased rates of
resistance in methicillin-resistant S. aureus.
Our targeted presurgical surveillance and decolonization program for methicillin-resistant
S. aureus with mupirocin–chlorhexidine started in
2006, followed by facility-wide surveillance and
provider-initiated decolonization in 2007. Using
Pearson correlation coefficients, we have been
evaluating mupirocin resistance in S. aureus since
June 2004 and assessing the effect of facilitylevel use of mupirocin.1-4 In 980 isolates of methicillin-resistant S. aureus, we found that an increase
in the monthly use of mupirocin had a significant
association with subsequent increases in low-level
resistance after 1 month (P = 0.05) and in highlevel resistance after 2 months (P = 0.03). Mupiro-
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cin resistance in methicillin-susceptible S. aureus
was uncommon during the 4.5-year period (9 cases
of resistance in 342 isolates), and the use of mupirocin was not correlated with lagged resistance in
the subsequent 12 months. These data suggest an
ecologic association between mupirocin use and
resistance in methicillin-resistant S. aureus. These
findings have implications for facilities instituting decolonization programs, since the increased
use of mupirocin may reduce the drug’s effectiveness.
Kerry L. LaPlante, Pharm.D.
University of Rhode Island
Kingston, RI
kerrytedesco@uri.edu
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methicillin-resistant S. aureus). Without screening,
appropriate switching from cefazolin to vancomycin often does not happen. In one cited study,4
surgeons routinely switched antibiotics, and methi
cillin-susceptible S. aureus caused the only surgicalsite infection in a patient who did not receive
mupirocin. In another study,3 surgeons did not
switch antibiotics, and methicillin-resistant S. aureus was rare and prophylaxis usually appropriate. In a third study,5 which was focused on
patients with methicillin-resistant S. aureus, those
who underwent decolonization also received appropriate perioperative prophylaxis, whereas the
other patients who were colonized with methicillin-resistant S. aureus usually did not receive a
glycopeptide, a factor that may have influenced the
development of 29 surgical-site infections with
the methicillin-resistant strain.
One advantage of screening is that colonized
patients can be isolated to prevent spread. More
than 30 studies have shown that active detection
and isolation were effective at controlling methicillin-resistant S. aureus infections among surgical patients, and 12 studies of cost-effectiveness
reported savings with such prophylaxis.
Barry M. Farr, M.D.
University of Virginia Health System
Charlottesville, VA
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